Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$405M in Q4 2025 → $630M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Lb Pharmaceuticals Inc | 7.8% | Added 15% | 1,523,022 | $49.4M |
| Nurix Therapeutics Inc | 6.1% | Trimmed 9.8% | 1,573,220 | $38.2M |
| IH Immunocore Hldgs PLC | 5.4% | Added 56% | 1,063,234 | $33.8M |
| First Tracks Biotherapeutics | 4.8% | New | 1,514,000 | $30.5M |
| 4M 4d Molecular Therapeutics In | 4.7% | Added 71% | 2,227,917 | $29.6M |
| Biomarin Pharmaceutical Inc | 4.7% | New | 512,000 | $29.3M |
| Design Therapeutics Inc | 4.6% | Added 135% | 2,001,282 | $29M |
| Xenon Pharmaceuticals Inc | 4.2% | Unchanged | 440,000 | $26.6M |
| Mirum Pharmaceuticals Inc | 4.2% | Trimmed 33% | 223,312 | $26.1M |
| Insmed Inc | 3.9% | New | 230,331 | $24.6M |
| Cytokinetics Inc | 3.9% | Trimmed 4.0% | 288,089 | $24.5M |
| Syndax Pharmaceuticals Inc | 3.9% | Added 58% | 1,110,000 | $24.3M |
| Neurogene Inc | 3.6% | Trimmed 8.7% | 714,885 | $22.5M |
| Kailera Therapeutics Inc | 3.4% | New | 984,786 | $21.7M |
| Revolution Medicines Inc | 3.4% | Trimmed 53% | 115,750 | $21.7M |
| Inhibikase Therapeutics Inc | 2.9% | Added 12% | 9,051,318 | $18.4M |
| Incyte Corp | 2.8% | New | 155,000 | $17.6M |
| Avalo Therapeutics Inc | 2.6% | New | 891,881 | $16.5M |
| Moonlake Immunotherapeutics | 2.3% | New | 750,000 | $14.6M |
| Faeth Therapeutics Inc | 2.0% | Added 312% | 515,335 | $12.9M |
| X4 Pharmaceuticals Inc | 1.9% | Unchanged | 2,571,478 | $12M |
| Opus Genetics Inc | 1.8% | Added 449% | 2,743,658 | $11.3M |
| Sol-gel Technologies Ltd | 1.6% | Added 63% | 139,445 | $10.3M |
| Aura Biosciences Inc | 1.6% | New | 1,443,333 | $10.2M |
| Century Therapeutics Inc | 1.6% | Added 69% | 4,134,969 | $10.1M |
| Inventiva Sa | 1.6% | Unchanged | 2,657,997 | $10M |
| Camp4 Therapeutics Corp | 1.3% | Trimmed 0.3% | 1,932,937 | $8.45M |
| Altimmune Inc | 1.3% | New | 2,660,000 | $8.09M |
| Minerva Neurosciences Inc | 1.3% | Unchanged | 1,419,000 | $7.88M |
| Promis Neurosciences Inc | 1.2% | Unchanged | 557,103 | $7.33M |
| Onkure Therapeutics Inc | 1.0% | New | 1,438,456 | $6.56M |
| Forte Biosciences Inc | 0.9% | New | 273,181 | $5.81M |
| RA Research Alliance Corp Iii | 0.8% | New | 500,000 | $5.35M |
| Vtv Therapeutics Inc | 0.5% | Trimmed 39% | 85,192 | $3.21M |
| Imagenebio Inc | 0.3% | New | 282,004 | $1.66M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | Exited | −662,470 | −$38.5M | — |
| Definium Therapeutics Inc | Exited | −1,738,110 | −$32.9M | — |
| First Tracks Biotherapeutics | New | +1,514,000 | +$30.5M | 4.8% |
| Biomarin Pharmaceutical Inc | New | +512,000 | +$29.3M | 4.7% |
| Insmed Inc | New | +230,331 | +$24.6M | 3.9% |
| Revolution Medicines Inc | Trimmed | −129,250 | −$24.2M | 3.4% |
| Arcus Biosciences Inc | Exited | −1,047,935 | −$22.6M | — |
| Kailera Therapeutics Inc | New | +984,786 | +$21.7M | 3.4% |
| Incyte Corp | New | +155,000 | +$17.6M | 2.8% |
| Design Therapeutics Inc | Added | +1,149,269 | +$16.6M | 4.6% |
Showing the 10 largest of 35 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Exited | −1,419,406 | −$37.9M | — |
| MM Mind Medicine Mindmed Inc | Exited | −2,568,110 | −$34.4M | — |
| Definium Therapeutics Inc | New | +1,738,110 | +$32.9M | 7.5% |
| Mirum Pharmaceuticals Inc | Added | +301,450 | +$27.8M | 7.1% |
| Revolution Medicines Inc | New | +245,000 | +$23.8M | 5.5% |
| Cytokinetics Inc | New | +300,000 | +$19.8M | 4.5% |
| Tyra Biosciences Inc | Exited | −700,000 | −$18.4M | — |
| Syndax Pharmaceuticals Inc | New | +701,821 | +$16.4M | 3.8% |
| Amicus Therapeutics Inc | Exited | −1,043,313 | −$14.9M | — |
| Apogee Therapeutics Inc | Exited | −192,000 | −$14.5M | — |
Showing the 10 largest of 32 changes.
Loading...
